In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc ... with a steady demand for products and services ...

Premier products in Merck’s portfolio include Keytruda ... Overall MRK ranks 2nd on our list of the best US stocks for foreign investors right now. While we acknowledge the growth potential ...

In this piece, we will take a look at where Merck & Co., Inc. (NYSE:MRK) ranks on the list of the top UBS AI ... stocks soared as the demand for tech products rose due to lockdowns and stay ...